Allergy Therapeutics (GB:AGY) has released an update.
Allergy Therapeutics has successfully advanced their VLP Peanut PROTECT trial, reporting no safety concerns in recent cohorts of both peanut allergic patients and healthy subjects who received increasing doses of the company’s novel peanut allergy vaccine candidate. The latest findings bolster confidence in the vaccine’s safety profile, with the trial set to continue escalating doses to gather key efficacy data. The positive results mark a significant step towards a Phase IIb study, indicating potential progress in peanut allergy immunotherapy.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
